Back to top
more

Cocrystal Pharma (COCP)

(Delayed Data from NSDQ)

$1.56 USD

1.56
29,490

+0.05 (2.98%)

Updated Apr 26, 2024 03:57 PM ET

After-Market: $1.55 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.

General Information

Cocrystal Pharma, Inc

19805 N. CREEK PARKWAY

BOTHELL, WA 98011

Phone: 877-262-7123

Fax: NA

Web: http://www.cocrystalpharma.com

Email: jcain@lhai.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/20/2024

EPS Information

Current Quarter EPS Consensus Estimate -0.54
Current Year EPS Consensus Estimate -2.30
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/20/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 1.51
52 Week High 3.29
52 Week Low 1.33
Beta 1.34
20 Day Moving Average 14,799.40
Target Price Consensus 8.67

COCP

% Price Change
4 Week 11.07
12 Week -3.42
YTD -9.71
% Price Change Relative to S&P 500
4 Week 14.43
12 Week -6.09
YTD -15.55
Share Information
Shares Outstanding (millions) 10.17
Market Capitalization (millions) 15.82
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 20.00%
vs. Previous Quarter -7.32%
   
Sales Growth
vs. Previous Year NA%
vs. Previous Quarter NA%
   
Price Ratios
Price/Book 0.60
Price/Cash Flow NA
Price / Sales NA
ROE
3/31/24 NA
12/31/23 -59.62
9/30/23 -54.10
ROA
3/31/24 NA
12/31/23 -54.62
9/30/23 -51.18
Current Ratio
3/31/24 NA
12/31/23 8.92
9/30/23 16.74
Quick Ratio
3/31/24 NA
12/31/23 8.92
9/30/23 16.74
Operating Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Net Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Pre-Tax Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Book Value
3/31/24 NA
12/31/23 2.59
9/30/23 3.02
Inventory Turnover
3/31/24 NA
12/31/23 NA
9/30/23 NA
Debt-to-Equity
3/31/24 NA
12/31/23 0.00
9/30/23 0.00
Debt to Capital
3/31/24 NA
12/31/23 0.00
9/30/23 0.00